Status:
COMPLETED
Bioequivalency Study of Meloxicam Tablets Under Fasting Conditions
Lead Sponsor:
Roxane Laboratories
Conditions:
Inflammation
Eligibility:
All Genders
18-45 years
Phase:
NA
Brief Summary
The objective of this study was the bioequivalence of a Roxane Laboratories' Meloxicam tablets, 15 mg, to Mobic® Tablets, 15 mg (Boehringer Ingelheim) under fasting conditions using a single-dose, ran...
Eligibility Criteria
Inclusion
- No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening.
Exclusion
- Positive test for HIV, Hepatitis B, or Hepatitis C.
- Treatment with known enzyme altering drugs.
- History of allergic or adverse response to Meloxicam or any comparable or similar product.
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2005
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT00618163
Start Date
March 1 2005
End Date
April 1 2005
Last Update
January 23 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novum Pharmaceutical Research Services
Houston, Texas, United States, 77042